key: cord-0968409-5w5gmovh authors: Jegerlehner, Sabrina; Suter-Riniker, Franziska; Jent, Philipp; Bittel, Pascal; Nagler, Michael title: Diagnostic accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings date: 2021-07-07 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.07.010 sha: 8f805b83ab9f2cf4d63db7e606e198324472302c doc_id: 968409 cord_uid: 5w5gmovh BACKGROUND: Laboratory tests are a mainstay in managing the COVID-19 pandemic, and high hopes are placed on rapid antigen tests. However, the accuracy of rapid antigen tests in real-life clinical settings is unclear because adequately designed diagnostic accuracy studies are essentially lacking. OBJECTIVES: We aimed to assess the diagnostic accuracy of a rapid antigen test to diagnose SARS-CoV-2 infection in a primary/ secondary care testing facility. METHODS: Consecutive individuals presented at a COVID-19 testing facility affiliated to a Swiss University Hospital were recruited (n=1’465%). Nasopharyngeal swabs were obtained, and the Roche/ SD Biosensor rapid antigen test was conducted in-parallel with two real-time PCR (reference standard). RESULTS: Among 1’465 patients recruited, RT-PCR was positive in 141 individuals, corresponding to a prevalence of prevalence 9.6%. The Roche/ SD Biosensor rapid antigen test was positive in 94 patients (6.4%), and negative in 1’368 individuals (93.4%). The overall sensitivity of the rapid antigen test was 65.3% (95% confidence interval, CI, 56.8, 73.1), the specificity was 99.9% (95%CI 99.5, 100.0). In asymptomatic individuals, the sensitivity was 44.0% (95%CI 24.4, 65.1). CONCLUSIONS: The diagnostic accuracy of the SARS-CoV-2 Roche/SD Biosensor rapid antigen test to diagnose a SARS-CoV-2 infection in a primary/ secondary care testing facility was considerably lower compared to manufacturers’ data. Widespread application in this setting might lead to a considerable number of individuals falsely classified as SARS-CoV-2 negative. Background: Laboratory tests are a mainstay in managing the COVID-19 pandemic, and high hopes are placed on rapid antigen tests. However, the accuracy of rapid antigen tests in real-life clinical settings is unclear because adequately designed diagnostic accuracy studies are essentially lacking. Objectives: We aimed to assess the diagnostic accuracy of a rapid antigen test to diagnose SARS-CoV-2 infection in a primary/ secondary care testing facility. Methods: Consecutive individuals presented at a COVID-19 testing facility affiliated to a Swiss University Hospital were recruited (n=1'465%). Nasopharyngeal swabs were obtained, and the Roche/ SD Biosensor rapid antigen test was conducted inparallel with two real-time PCR (reference standard). Results: Among 1'465 patients recruited, RT-PCR was positive in 141 individuals, corresponding to a prevalence of prevalence 9.6%. The Roche/ SD Biosensor rapid antigen test was positive in 94 patients (6.4%), and negative in 1'368 individuals (93.4%). The overall sensitivity of the rapid antigen test was 65.3% (95% confidence interval, CI, 56.8, 73 .1), the specificity was 99.9% (95%CI 99.5, 100.0). In asymptomatic individuals, the sensitivity was 44.0% (95%CI 24.4, 65.1). The diagnostic accuracy of the SARS-CoV-2 Roche/SD Biosensor rapid antigen test to diagnose a SARS-CoV-2 infection in a primary/ secondary care testing facility was considerably lower compared to manufacturers' data. Widespread application in this setting might lead to a considerable number of individuals falsely classified as SARS-CoV-2 negative. Governments worldwide are pinning high hopes on COVID-19 testing programs using rapid antigen tests to ease the burden on health systems and lift restrictions that have disrupted workplaces and led to pervasive socio-economic costs (Crozier et al., 2021) (Dinnes et al., 2020) . In contrast to a standard laboratory-based reverse transcription-polymerase chain reaction (RT-PCR), rapid antigen tests require much less technical expertise and laboratory capacity (Mattiuzzi et al., 2020) . In terms of a point-of-care device, these tests can be performed by minimally trained persons in various primary and even community settings (Dinnes et al., 2020) . Besides, test results are delivered within 5 to 30 minutes and are available within a single clinical encounter (Mattiuzzi et al., 2020) . Thus, rapid antigen tests might overcome the drawbacks of RT-PCR in terms of availability, throughput, and turnaround time (Mattiuzzi et al., 2020) . These limitations of RT-PCR are recognized as a major barrier to the broad implementation of urgent testing capabilities for everybody (Iacobucci, 2020 , Mattiuzzi et al., 2020 , Thornton, 2020 . Thus, rapid antigen tests might support the almost universal strategy of early diagnosis and timely isolation of individuals with SARS-CoV-2 infection (Mattiuzzi et al., 2020) . Early diagnosis of SARS-CoV-2 infection and timely isolation is most often addressed by testing individuals with symptoms or known exposure to patients (Dinnes et al., 2020) . Testing facilities aiming to confirm or rule out SARS-CoV-2 infection in this population are affiliated at various primary or secondary care facilities. More recently, tests are even provided in the community setting, or even self-testing is applied. As an essential pre-requirement, applied laboratory tests must be accurate to be of value in such settings (Dinnes et al., 2020) . This means the number of patients with SARS-CoV-2 infection missed by the respective laboratory test must be low (false-negatives). Accordingly, the number of individuals falsely claimed to be infected must be low (false-positives). These performance measures refer to the diagnostic accuracy of a test, which can only be determined in an adequately designed diagnostic accuracy study (Bossuyt et al., 2015 , Bossuyt, 2007 , Crozier et al., 2021 , Dinnes et al., 2020 , Mallett et al., 2012 , Whiting et al., 2011 . To assess the accuracy of a rapid antigen test to diagnose SARS-CoV-2 infection in a testing facility in secondary or primary care, diagnostic accuracy studies are required which are conducted in defined clinical settings. To date, these studies are essentially lacking (Dinnes et al., 2020) . In a prospective cross-sectional study, we aimed to assess the diagnostic accuracy of a rapid antigen test to diagnose SARS-CoV-2 infection in a primary/ secondary care testing facility. The AgiP study is a prospective cross-sectional study conducted at a COVID-19 testing facility affiliated to a Swiss University Hospital. Consecutive individuals presenting on their own between January and March 2021 were recruited. Inclusion criteria were (a) suspected SARS-CoV-2 infection, (b) age ≥ 18 years, and (c) signed informed consent. Exclusion criteria were (a) clinical warning signs which made emergency medical care necessary (CDC, 2020). A flow sheet is given in Figure 1 . The COVID-19 testing facility is one of the largest testing facilities in the greater Bern are, affiliated to a large specialized laboratory running high-troughput RT-PCR (Brigger et al., 2021) . During the study period, individuals were instructed by authorities to present themselves in case of symptoms consistent with SARS-CoV-2. Authorities also referred patients in case of exposure to infected individuals. Some individuals presented for other reasons (e.g., travel requirements or for shortening quarantine measures). The study protocol was approved by the appropriate ethical committee (Kantonale Ethikkommission Bern #2020-02729) and the institutional authorities. All participants signed informed consent. The study was conducted in accordance with the declaration of Helsinki. Individuals were recruited and informed by specially trained medical staff before the consultation. Following informed consent, patients filled a questionnaire which was created following instructions of the Swiss Federal Office of Public Health and the recommendations of the Centers for Disease Control and Prevention (CDC) (CDC, 2020 , Health, 2021a . Acute respiratory syndrome was defined as a new onset of respiratory illness symptoms (sore throat, cough, shortness of breath, and chest pain) (Health, 2021a). Additional symptoms were fever, muscle or body aches, loss of taste or smell, confusion or poor general condition. During the subsequent consultation, the answers to the questionnaire were checked by a particularly trained physician. A specially trained nurse collected nasopharyngeal specimens. All nurses completed a training course which was prepared following established guidelines on swab collection (CDC, 2021) . Nurses were supervised within the first days of practice. Swabs were collected using iClean Specimen Collection Flocked Swabs (Cleanmo Technology Co., Shenzhen, China) and Liofilchem Viral Transport Medium (Italy). Sample material was stored at 4° C and processed within 6 hours (antigen test) or 12 hours (RT-PCR), respectively. Coded clinical data and laboratory test results were stored in separate databases and merged before analysis. Using the same sample material, the Roche/ SD Biosensor SARS-CoV-2 rapid antigen test was conducted in parallel by a trained medical laboratory technician (without being aware of the RT-PCR results). Quality control was performed daily. Instructions of the manufacturer were strictly followed (Package leaflet; Roche diagnostics, Mannheim, Germany). Briefly, three drops of the extracted sample were applied to the specimen well of the test device. The test result was recorded after 15 to 30 minutes. The result was only considered valid if the control line was visible. Even faint test lines were considered positive. As a reference standard test defining the presence of COVID-19, two real-time PCR (RT-PCR) assays were conducted as previously described (Roche cobas® SARS-CoV-2; Seegene Allplex 2019-nCoV) (Brigger et al., 2021) . Analyses were performed according to the manufacturers' instructions on a STARlet IVD System or a cobas 8800 system, respectively. RT-PCR was done in line with clinical practice, and laboratory technicians were unaware of the index test results. Detectable SARS-CoV-2 below or at a cycle threshold of 40 were considered positive. Commercially available quality control was conducted with each test run. Patient characteristics were given in numbers (percentages) or mean (standard deviation) as appropriate. Two-by-two tables were created using RT-PCR results as reference standard test and the Roche/ SD Biosensor as index test. Sensitivities and specificities were calculated accordingly. Data were presented overall and in salient subgroups. As a sensitivity analysis, diagnostic accuracy measures were calculated for additional cycling thresholds (CT) of the RT-PCR. A method proposed by Bujang et al. were used for a power analysis (Bujang and Adnan, 2016 Overall, 1'465 individuals were eventually included (Figure 1) . The majority of patients presented with symptoms consistent with COVID-19 (n=1'114; 76.0%). Fiftynine individuals were referred because of exposure to infected individuals (4.0%). Other reasons (e.g., travel requirements) were present in 293 patients (20.0%). The mean age was 36.4 years (standard deviation, SD, 14.0), 787 individuals were female (53.7%). Detailed patient characteristics are given in Table 1 . Insufficient sample material for determination of the rapid antigen test was present in 3 individuals. One-hundred forty-one individuals tested positive with the RT-PCR, corresponding to a prevalence of 9.6%. Complete agreement between both RT-PCR assays was observed. The Roche/ SD Biosensor rapid antigen test was positive in 94 patients (6.4%), and negative in 1'368 individuals (93.4%). The overall sensitivity of the Roche/ SD Biosensor rapid antigen test was 65.3 % (95% confidence interval, CI, 56.8, 73.1), the specificity was 99.9 (95%CI 99.5, 100.0). The number of false-negative test results was 49, and the number of false-positives was 2 (n=92 true positives; n=1'319 true negatives). The sensitivity of the rapid antigen test was higher in patients with any symptom (69.8%), acute respiratory syndrome (69.2%), and fever (73.9%). The sensitivity was lower in asymptomatic individuals (44%) and other subgroups. Detailed sensitivities and specificities according to age group, presence of symptoms, or billing mode are reported in Figure 2 . The sensitivity of the rapid antigen test in relation to adapted cycle thresholds are given in Figure 3 . The sensitivity ranged from 65.3% (CT 40) to 84.4% (CT 30). We conducted a prospective cross-sectional study to assess the diagnostic accuracy of a rapid antigen test to diagnose SARS-CoV-2 infection in the real-life clinical setting of a primary/ secondary care testing facility. Among 1'465 patients included, 351 presented without any symptom. The overall sensitivity of the rapid Roche/ SD Biosensor rapid antigen test was 65.3%, which is substantially lower than previous studies and manufacturer's data (Mattiuzzi et al., 2020) . Besides, the sensitivity was 44% in patients without any symptom. Various studies analyzing the diagnostic accuracy of rapid antigen tests have been conducted, and a systematic review conducted by the Cochrane Collaboration summarized these data (Dinnes et al., 2020) . The authors raised major methodological concerns and a considerable risk of bias in all previous studies. In particular, the applicability is estimated to be low because of biased patient selection. In contrast to these studies, we have paid close attention to all the requirements of diagnostic accuracy studies: (a) an adequately powered prospective cross-sectional design studying a clearly defined clinical question, (b) selection of an appropriate study population (real-life clinical setting), (c) accurate determination of the index test, (d) rigorous choice and determination of the reference standard test, and (e) optimal flow and timing. We believe that this difference in study design and methodological quality explains the significant differences in sensitivities obtained. As a limitation, our data were obtained in a particular clinical setting in a primary/ secondary care facility in Switzerland. The diagnostic accuracy measures will differ in other clinical settings because of differences in prevalence and patient population. We believe, however, that the diagnostic accuracy measures in other real-life clinical settings will more likely be like our results rather than very optimistic numbers provided by the manufacturers. Besides, one particular assay of one manufacturer was studied, and the results cannot straightforward be applied to other assays. However, without similar studies conducted with other assays, we have no good arguments to assume that other tests will perform better. As another limitation, the adequate cycle threshold to identify a SARS-CoV-2 infection is disputed and some authors argue that a lower threshold would be sufficient, particularly with a few on infectiousness. However, a lower cycle threshold is not established and the sensitivity was even limited with lower CT values (Figure 3) . What do our results mean in clinical practice? Using the sensitivity obtained in our study, and considering a similar clinical setting in other Swiss testing facilities, we calculated the numbers of false-negative test results within one week in Switzerland. Estimated 2'280'000 rapid antigen-tests were done between 8 th and 15 th of June 2021 and the Roche/ SD Biosensor will be used in the majority of cases (Health, 2021b). Considering a proportion of positive tests of 6.8% would result in 155'280 individuals correctly identified with a SARS-CoV-2 infection but 82'514 individuals falsely classified as SARS-CoV-2 negative. While feeling safe, these individuals would probably contribute to SARS-CoV-2 transmission by inappropriate social contacts. Thus, negative test results should be treated with great caution, especially in asymptomatic individuals. In conclusion, the diagnostic accuracy of the SARS-CoV-2 Roche/SD Biosensor rapid antigen test to diagnose a SARS-CoV-2 infection in a primary/ secondary care testing facility was considerably lower compared to manufacturers' data. Widespread application in this setting might lead to a considerable number of individuals falsely classified as SARS-CoV-2 negative. The study was approved by the local ethical committee (Kantonale Ethikkommission Bern # 2020-02729). The database is available on request at the corresponding author. SJ collected data, wrote the manuscript, and contributed to study design and interpretation of results. FSR and PB collected data, contributed to study design and interpretation of the results, and revised the manuscript. PJ contributed to study design, interpretation of the results, and revised the manuscript. MN designed the study, analyzed and interpreted the data, and wrote the manuscript. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies Studies for Evaluating Diagnostic and Prognostic Accuracy Accuracy of serological testing for SARS-CoV-2 antibodies: First results of a large mixedmethod evaluation study Requirements for Minimum Sample Size for Sensitivity and Specificity Analysis Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing Put to the test: use of rapid testing technologies for covid-19 SARS-CoV2 Rapid Antigen Test; Package leaflet Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection Coronavirus: Disease, symptoms, treatment; 2021a COVID-19 Switzerland, Epidemiological course Covid-19: Government faces criticism over pound500m plan to pilot mass testing Interpreting diagnostic accuracy studies for patient care Making sense of rapid antigen testing in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics. Diagnosis (Berl) Covid-19: Delays in getting tests are keeping doctors from work, health leaders warn QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies Age, mean (SD) MN received research support from Roche diagnostics outside of the present work.All other authors declare that no conflict of interest exist.